

Technology Advisory Committee A Interests Register

Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] [ID4066]

Publication Date: 11/10/2023

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Interest ceased | Comments |
|------------------|------------------------|------------------------------|---|-------------------|-----------------|---|
| Becky Pennington | TAC A Committee Member | Direct - Financial Interests | Becky received consultancy fees from Roche and Takeda for research/advice into including carer health-related quality of life in economic evaluation. Neither project was drug or disease-area specific and did not relate to either bevacizumab or alogliptin. | 19/05/2023 | N/A | It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal. |
| Becky Pennington | TAC A Committee Member | Direct - Financial Interests | Becky received consultancy fees from Takeda & Roche for methods research on carers' HRQL (not specific to any drug / indication and not related to the topics here). | 10/07/2023 | N/A | It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Interest ceased | Comments |
|------------------------|---|---|--|-------------------|-----------------|---|
| Dr Steve Edwards | TAC A Committee Member/EAG | | Steve was a member of the EAG for olaparib (ID4066) and so could not attend as a committee member for the topic. | 17/05/2023 | N/A | It was agreed that Steve's declaration would prevent him from participating in discussions on this appraisal as a committee member. |
| Steven Lloyd | TAC C Vice Chair | Non-Financial Professional & Personal Interests | Comparator company is Pfizer – Steve has undertaken paid educational work for covid treatments for HCPs sponsored by this company in the past. | 01/06/2023 | N/A | It was agreed that Steven's declaration would not prevent him from participating in discussions on this appraisal. |
| Anna Hudson | Head of Support Services at Ovacom Ovarian Cancer Charity | Indirect - financial | Ovacom Ovarian Cancer Charity has received funding from various drug companies, but no conflicts of interest. | 01/06/2023 | N/A | It was agreed that Anna's declaration would not prevent her from participating in discussions on this appraisal. |
| Professor Iain McNeish | Professor of Oncology at Imperial | Direct – financial | Iain has sat on Advisory Boards for AstraZeneca – these have all related to the | 06/10/2022 | N/A | It was agreed that Iain's declaration would not prevent him from |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Interest ceased | Comments |
|------------------------|--|----------------------|---|-------------------|-----------------|--|
| | College London | | use of PARP inhibitor therapy in ovarian cancer. | | | participating in discussions on this appraisal. |
| Professor Iain McNeish | Professor of Oncology at Imperial College London | Indirect – financial | Iain's My institution, Imperial College London, has received grant income from AstraZeneca. | 06/10/2022 | N/A | It was agreed that Iain's declaration would not prevent him from participating in discussions on this appraisal. |